Firebrick Pharma Ltd (ASX: FRE) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Firebrick Pharma Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Firebrick Pharma Ltd (ASX: FRE)
Latest News
Share Market News
Why is the Firebrick Pharma share price blazing 28% on Wednesday?
Share Gainers
On fire! Firebrick (ASX:FRE) share price surges another 22% on second day of trade
IPOs
Firebrick Pharma (ASX:FRE) share price launches 165% following ASX IPO
IPOs
Firebrick Pharma (ASX:FRE) is floating on the ASX today. Here's what you need to know
FRE ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Firebrick Pharma Ltd
Firebrick Pharma Ltd is an Australian pharmaceutical developer. It is engaged in the development and commercialization of povidone-iodine (PVP-I) products under the Nasodine brand. Its Nasodine Nasal Spray which is in the commercializationphase, is a broad-spectrum anti-viral spray, designed to be an effective treatment and prevention of respiratory viral infections such as the common cold. In parallel, the company is also engaged in the development of the follow-on Nasodine brand products.
FRE Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
21 Nov 2024 | $0.05 | $0.00 | 0.00% | 88,363 | $0.05 | $0.05 | $0.05 |
20 Nov 2024 | $0.05 | $0.00 | 0.00% | 25,000 | $0.05 | $0.05 | $0.05 |
18 Nov 2024 | $0.05 | $0.00 | 0.00% | 1,200 | $0.05 | $0.05 | $0.05 |
15 Nov 2024 | $0.06 | $0.01 | 19.23% | 35,000 | $0.06 | $0.06 | $0.06 |
14 Nov 2024 | $0.05 | $0.00 | 0.00% | 4,000 | $0.05 | $0.05 | $0.05 |
13 Nov 2024 | $0.05 | $0.00 | 0.00% | 13,771 | $0.05 | $0.05 | $0.05 |
12 Nov 2024 | $0.05 | $-0.01 | -16.67% | 67,528 | $0.06 | $0.06 | $0.05 |
11 Nov 2024 | $0.06 | $0.00 | 0.00% | 137,011 | $0.06 | $0.06 | $0.06 |
07 Nov 2024 | $0.06 | $0.00 | 0.00% | 16,857 | $0.06 | $0.06 | $0.06 |
06 Nov 2024 | $0.06 | $0.00 | 0.00% | 24,180 | $0.06 | $0.06 | $0.06 |
04 Nov 2024 | $0.06 | $0.00 | 0.00% | 73,945 | $0.06 | $0.06 | $0.06 |
01 Nov 2024 | $0.06 | $0.00 | 0.00% | 85,706 | $0.06 | $0.06 | $0.06 |
31 Oct 2024 | $0.06 | $0.00 | 0.00% | 5,516 | $0.06 | $0.06 | $0.06 |
30 Oct 2024 | $0.06 | $0.00 | 0.00% | 71,409 | $0.06 | $0.06 | $0.06 |
28 Oct 2024 | $0.06 | $0.00 | 0.00% | 29,222 | $0.06 | $0.06 | $0.06 |
25 Oct 2024 | $0.06 | $0.00 | 0.00% | 256,625 | $0.06 | $0.06 | $0.06 |
24 Oct 2024 | $0.06 | $0.00 | 0.00% | 14,000 | $0.06 | $0.06 | $0.06 |
22 Oct 2024 | $0.06 | $0.00 | 0.00% | 74,389 | $0.06 | $0.06 | $0.06 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
10 Oct 2024 | Peter Molloy | Buy | 454,545 | $25,000 |
Participation in share purchase plan.
|
10 Oct 2024 | Stephen Goodall | Buy | 181,818 | $10,000 |
Participation in share purchase plan.
|
27 Jun 2024 | Peter Molloy | Buy | 500,000 | $28,437 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Dr Peter Laurence Molloy | FounderChief Executive OfficerExecutive ChairmanExecutive Director | Apr 2012 |
Dr Molloy was a Managing Director of Australia/NZ operations and later Vice President for Strategic Marketing, responsible for the marketing of hundreds of pharmaceuticals across 22 countries. During his pharmaceutical career, he has directly launched 23 new pharmaceutical products and executed 40 international licensing or distribution deals., As CEO of four biotech companies, he has led R&D programs, moved several drugs from research into human clinical trials, and executed valuable international pharmaceutical partnerships. Dr Molloy was responsible for the creation and launch in Australia of Betadine Sore Throat Gargle, which subsequently became a leading OTC product in Australia and the inspiration for the development of Nasodine.
|
Dr Stephen Francis Goodall | FounderChief Operating OfficerExecutive Director | Apr 2012 |
Dr Goodall has a track record in intellectual property, pharmaceutical development, manufacturing, regulatory strategy and clinical development. He was instrumental in developing the intellectual property that underpins the Firebrick patent. Previously, he was Chief Operating Officer of Viralytics. Previously, he was the Director of Pharmaceutical Development at Vapotronics, where he managed all aspects of inhaled drug development and formulation and before that, Director of Development at AGEN Biomedical for 11 years. He has experience in the preclinical, IND, regulatory and human clinical phases of drug development. He also has an impressive background in process development, production scale-up and GMP manufacturing for pharmaceuticals. Dr Goodall is a founder of Firebrick and co-inventor on all the key Firebrick patents.
|
Dr Phyllis Irene Gardner | Non-Executive Director | Nov 2020 |
Dr Gardner is Professor of Medicine at Stanford University and is a scientist, entrepreneur and venture capitalist, and has been a director of many prominent public biotechnology companies in the United States.
|
Mr Stephen Buckley | Company Secretary |
-
|
|
Stephen Buckley | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Aquarico Pty Ltd <P & C Molloy Family A/C> | 30,326,472 | 15.53% |
Biotech Design Pty Ltd | 30,326,472 | 15.53% |
GZ Family Holdings Pty Ltd <GZ Family A/C> | 23,400,000 | 11.98% |
BNP Paribas Noms Pty Ltd | 3,250,017 | 1.66% |
Ms Helen Frances Morgan | 2,744,507 | 1.41% |
Mr Ivan Kaufman | 2,550,000 | 1.31% |
Dr Jonathan Bryden Dalitz & Mrs Michelle Anne Dalitz <Dalitz Super Fund A/C> | 2,500,000 | 1.28% |
Kashflow 18 LLC | 2,103,713 | 1.08% |
Zero Nominees Pty Ltd | 2,103,691 | 1.08% |
Mr Ian Douglas Robertson | 2,074,129 | 1.06% |
The Shed Man Pty Ltd | 1,750,000 | 0.90% |
GB & JK Porter Pty Ltd <GB & JK Porter S/F A/C> | 1,500,000 | 0.77% |
Bnp Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> | 1,206,028 | 0.62% |
Greenford Pty Ltd <Kluger Super Fund A/C> | 1,200,000 | 0.61% |
GZ Super Investments Pty Ltd <GZ Superannuation Fund A/C> | 1,200,000 | 0.61% |
Mrs Jill Robin Margo | 1,183,100 | 0.61% |
Mrs Christine Louise Molloy | 1,030,000 | 0.53% |
Mr Michael Graeme Duckworth | 1,012,358 | 0.52% |
Davivaro Pty Ltd <Rosenfeld Super Fund A/C> | 1,000,000 | 0.51% |
Blake Nominees Pty Ltd <M And T Super Fund A/C> | 1,000,000 | 0.51% |